Risk of infections in renal cell carcinoma (RCC) and non-RCC patients treated with mammalian target of rapamycin inhibitors
about
Risk of gastrointestinal events with sorafenib, sunitinib and pazopanib in patients with solid tumors: a systematic review and meta-analysis of clinical trialsRisk of Infectious Complications in Hemato-Oncological Patients Treated with Kinase InhibitorsRisk of Hyponatraemia in Cancer Patients Treated with Targeted Therapies: A Systematic Review and Meta-Analysis of Clinical TrialsAttributable Risk of Infection to mTOR Inhibitors Everolimus and Temsirolimus in the Treatment of Cancer.Higher Risk of Infections with PI3K-AKT-mTOR Pathway Inhibitors in Patients with Advanced Solid Tumors on Phase I Clinical Trials.Immunomodulation and Disease Tolerance to Staphylococcus aureusTreatment-related fatigue with sorafenib, sunitinib and pazopanib in patients with advanced solid tumors: an up-to-date review and meta-analysis of clinical trials.Does the nature of residual immune function explain the differential risk of non-melanoma skin cancer development in immunosuppressed organ transplant recipients?Kinase signalling pathways in endometriosis: potential targets for non-hormonal therapeutics.Paradoxical simultaneous regression and progression of lesions in a phase II study of everolimus in classic Kaposi sarcoma.Improving consolidation therapy in acute myeloid leukemia - a tough nut to crackmTOR inhibitors lower an intrinsic barrier to virus infection mediated by IFITM3Clinically-Relevant Rapamycin Treatment Regimens Enhance CD8+ Effector Memory T Cell Function In The Skin and Allow their Infiltration into Cutaneous Squamous Cell CarcinomaAddition of the mammalian target of rapamycin inhibitor, everolimus, to consolidation therapy in acute myeloid leukemia: experience from the UK NCRI AML17 trial
P2860
Q26822790-09CFE9CB-0E8D-4053-AC65-4ABB5DB23FA8Q26851417-12B643AD-7AD2-4E47-8F69-C199CA0C8816Q28551983-89F00D98-2E36-4C14-AF8D-966EC7C28879Q30243969-2D4FC764-6C51-4564-8D6A-F7A7BC86E167Q35462692-DE1C8134-3891-4769-8A4D-74AE8F99E7FEQ36409380-1E1DFC81-95F3-4978-ADF9-B2A8019605B1Q38177768-1EC425DF-DBD9-45A8-AEAB-074454AC2D0BQ38328785-7EEB297A-273A-476E-9902-7A470F3250EFQ38689176-67275FFB-C96F-43D2-9C30-E08EEFAB1F05Q51020785-AF862C56-164F-48F3-8D5F-2693373F768BQ57055454-321E1085-A5E9-43E0-8C4D-FE00CD27FA74Q57292151-7FCA80E7-F523-46B3-8B89-836D3D057CE6Q58037249-1BC00340-B6B0-4FE3-94D7-B848C96B6A2FQ58793734-690058EC-62FF-4B69-8F86-AC38DE73BF8C
P2860
Risk of infections in renal cell carcinoma (RCC) and non-RCC patients treated with mammalian target of rapamycin inhibitors
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Risk of infections in renal ce ...... target of rapamycin inhibitors
@en
type
label
Risk of infections in renal ce ...... target of rapamycin inhibitors
@en
prefLabel
Risk of infections in renal ce ...... target of rapamycin inhibitors
@en
P2093
P2860
P921
P356
P1476
Risk of infections in renal ce ...... target of rapamycin inhibitors
@en
P2093
C J Richards
D Y C Heng
G Sonpavde
M D Kaymakcalan
P L Nguyen
T K Choueiri
P2860
P2888
P304
P356
10.1038/BJC.2013.278
P407
P50
P5008
P577
2013-06-04T00:00:00Z
2013-06-25T00:00:00Z